Marengo’s STARt-002 selected for oral interim-results presentation at SITC
AI Summary- Marengo Therapeutics announced an oral presentation of STARt-002 interim results at SITC.
- November 7, 2026, is the scheduled presentation date for results from both expansion cohorts.
- STARt-002 is enrolling metastatic TNBC and HR-positive/HER2-negative breast cancer patients.